Danske Bank’s Nektar Therapeutics NKTR Stock Holding History

Danske Bank’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$144	Hold	2	–	–	﹤0.01%	1034
2025 Q4	$85	Hold	2	–	–	﹤0.01%	1441
2025 Q3	$114	Hold	2	–	–	﹤0.01%	1389
2025 Q2	$52	Buy	+2	New	+$22	﹤0.01%	1441

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Danske Bank's NKTR Position: Q1 2026 in Review

Danske Bank held its Nektar Therapeutics (NKTR) position steady in Q1 2026 at 2 shares worth $144. The position accounts for ﹤0.01% of the portfolio, ranked #1034.

Danske Bank first reported a position in NKTR in Q2 2025 and has held it in 4 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Danske Bank held 2 shares of Nektar Therapeutics worth $144 as of Q1 2026.
Danske Bank left its Nektar Therapeutics share count unchanged in Q1 2026.
Nektar Therapeutics made up ﹤0.01% of Danske Bank's portfolio in Q1 2026, its #1034 holding.
Danske Bank first reported a position in Nektar Therapeutics in Q2 2025 and has held it in 4 quarters since.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.